Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines
1997

NK109: A New Anti-Tumor Drug Against Drug-Resistant Cancer Cells

publication Evidence: moderate

Author Information

Author(s): F Kanzawa, K Nishio, T Ishida, M Fukuda, H Kurokawa, H Fukumoto, Y Nomoto, K Fukuoka, K Bojanowski, N Saijo

Primary Institution: National Cancer Center Research Institute

Hypothesis

NK109 will be effective against drug-resistant tumor cells due to its unique mechanism of action.

Conclusion

NK109 shows promising anti-tumor activity against various drug-resistant human tumor cell lines.

Supporting Evidence

  • NK109 was effective against doxorubicin-resistant human tumor cell lines.
  • NK109 accumulated in resistant cells and was not pumped out by P-glycoprotein.
  • Cisplatin-resistant human tumor cell lines were sensitive to NK109.
  • NK109 showed non-cross-resistance in various drug-resistant cell lines.
  • NK109's mechanism of action differs from that of etoposide.

Takeaway

NK109 is a new medicine that can fight cancer cells that usually resist treatment, making it a hopeful option for patients.

Methodology

The study involved testing NK109's effects on various human tumor cell lines, including drug-resistant variants, using in vitro assays and in vivo models in SCID mice.

Limitations

The clinical toxicity of NK109 needs further investigation before human trials can commence.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication